Junction Bioscience

AI Hypothesis Engine for Molecular Discovery

Y CombinatorWinter 2024ActiveHealthcareTherapeutics

What they do

Problem

Drug discovery for complex diseases like neuroinflammation is slow and uncertain due to limited understanding and control of underlying molecular mechanisms.

Solution

An autonomous AI hypothesis engine that iterates with laboratory chemistry to generate and validate molecular insights and advance best-in-class therapeutic candidates.

Who it's for

Biopharma and biotechnology R&D teams developing medicines, especially in neuroinflammation and immunology.

Founders

Brian Petkov

Founder

Brian is a theoretical physicist and drug hunter with degrees in mathematics and chemistry from Duke University and doctoral training from NYU. He was previously the first employee and Vice President at a computational drug design startup where he led the Machine Learning operation and grew a 30-person team to success on previously-undruggable targets.